Sugi Predict

Sugi Predict / Compounds / SCHEMBL349483

SCHEMBL349483

SCHEMBL349483

COC(=O)C1(c2ccccn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 4/20 0.47
▸ HSD17B10 Q99714 5/20 0.42
▸ CYP2D6 P10635 3/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ ITGA4 P13612 1/20 0.42
▸ ITGB7 P26010 1/20 0.42
▸ OPRK1 P41145 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ P2RY1 P47900 1/20 0.40
▸ RIPK1 Q13546 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28738251 0.92 HSD11B1 (0.50) HSD11B1HSD17B10CYP2D6CYP3A4TSHR
SCHEMBL25167294 0.91 OPRK1 (0.41) HSD11B1HSD17B10CYP2D6CYP3A4TSHR
SCHEMBL14341359 0.89 HSD11B1 (0.40) HSD11B1HSD17B10CYP2D6CYP3A4TSHR
SCHEMBL26451965 0.84 HSD17B10 (0.39) HSD11B1HSD17B10CYP2D6CYP3A4TSHR
SCHEMBL10696393 0.83 OPRM1 (0.50) HSD11B1HSD17B10OPRK1KDM4ELMNA
SCHEMBL5475313 0.82 CHRM2 (0.51) CYP2D6CYP3A4TSHRCYP2C19ALDH1A1
SCHEMBL19538478 0.80 HSD11B1 (0.47) HSD11B1ITGA4ITGB7ALDH1A1RIPK1
SCHEMBL29968154 0.80 HSD11B1 (0.41) HSD11B1CYP2D6CYP3A4ITGA4ITGB7
SCHEMBL28272357 0.79 OPRM1 (0.47) CYP2D6CYP3A4OPRK1
SCHEMBL28849863 0.79 CYP3A4 (0.40) HSD17B10CYP2D6CYP3A4TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957229-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2018-05-01 — — US disclosed
US-20170334847-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION 2017-11-23 — — US disclosed
US-9670154-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2017-06-06 — — US disclosed
EP-2963021-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Holdings Corporation (US) 2016-01-06 — — EP disclosed
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION 2015-11-19 — — US disclosed
US-9126927-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2015-09-08 — — US disclosed
EP-1756063-B1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-07-08 — — EP disclosed
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2012-01-19 — — US disclosed
US-8058288-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-11-15 — — US disclosed
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2010-10-07 — — US disclosed
EP-1756063-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-02-28 — — EP disclosed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 — — US disclosed
WO-2005110992-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2005-11-24 — — WO disclosed
CN-1046713-C Tetrahydroisoquinoline compounds, pharmaceutical compositions containing them, and their preparation and use KNORR CO LTD (GB) 1999-11-24 — — CN disclosed
US-5807868-A ANALGESICS; PSYCHOLOGICAL DISORDES; PARKINSON*S DIESASE;COGNITION ACTIVATORS; DRUG DEPENDENCE; DYSKINESIA KNOLL AKTIENGESELLSCHAFT (DE) 1998-09-15 — — US disclosed
US-5804586-A ANALGESICS, PSYCHOLOGICAL DISORDERS KNOLL AKTIENGESELLSCHAFT (DE) 1998-09-08 — — US disclosed
EP-0707570-B1 ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS KNOLL AG (DE) 1998-05-06 — — EP disclosed
CN-1128992-A Therapeutic agents KNORR CO LTD (DE) 1996-08-14 — — CN disclosed
EP-0707570-A1 ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS Knoll AG (DE) 1996-04-24 — — EP disclosed
WO-1995000489-A1 ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS KNOLL AG (DE) 1995-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334847-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD17B10 29/4885CYP2D6 358/4885
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD17B10 29/4885CYP2D6 358/4885
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD17B10 29/4885CYP2D6 358/4885
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD17B10 29/4885CYP2D6 358/4885
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD17B10 29/4885CYP2D6 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.